

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 June 2025 (12.06.2025)



(10) International Publication Number
WO 2025/122911 A1

(51) International Patent Classification:

A61K 31/395 (2006.01) *C07D 498/12* (2006.01)
A61K 31/41 (2006.01) *A61K 31/33* (2006.01)
A61K 31/415 (2006.01)

(21) International Application Number:

PCT/US2024/058939

(22) International Filing Date:

06 December 2024 (06.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/607,349 07 December 2023 (07.12.2023) US
63/725,441 26 November 2024 (26.11.2024) US

(71) Applicant: **BLOSSOMHILL THERAPEUTICS, INC.**

[US/US]; 3525 John Hopkins Court, Suite 100, San Diego,
California 92121 (US).

(72) Inventors: **ROGERS, Evan W.**; 3525 John Hopkins Court,

Suite 100, San Diego, California 92121 (US). **CUI, Jin-**

grong Jean; 3525 John Hopkins Court, Suite 100, San
Diego, California 92121 (US). **RUI, Eugene Yuanjin**;
3525 John Hopkins Court, Suite 100, San Diego, California
92121 (US). **SHAO, Z. Jesse**; 3525 John Hopkins Court,
Suite 100, San Diego, California 92121 (US). **GARRI-**
DO-MONTALBAN, Antonio; 3525 John Hopkins Court,
Suite 100, San Diego, California 92121 (US). **JIANG,**
Wanlong; 3525 John Hopkins Court, Suite 100, San Diego,
California 92121 (US). **CHANG, Chialu K.**; 3525 John
Hopkins Court, Suite 100, San Diego, California 92121
(US).

(74) Agent: **LEWALLEN, Daniel M.**; BARNES & THORN-
BURG LLP, 11 South Meridian Street, Indianapolis, Indi-
ana 46204 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,

(54) Title: INDAZOLE MACROCYCLE POLYMORPHS




FIG. 1A

(57) Abstract: This disclosure relates to polymorphs of (17E)-16-ethyl-8,12,14-trimethyl-2,11,12,14-tetrahydro-8H-3,5-ethenotripyra-
zolo[3,4-f:3',4'-j:4'',3''-n][1,4]oxazacyclopentadecin-13(10H)-one that are useful in the treatment of disease, such as cancer, in mam-
mals. This disclosure also relates to compositions including such polymorphs, and to methods of using such compositions in the treat-
ment of diseases, such as cancer, in mammals, especially in humans.

[Continued on next page]

WO 2025/122911 A1

MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*